Oxytocin inhibits hindpaw hyperalgesia induced by orofacial inflammation combined with stress

Yue-Xin Li¹,², Jia-Heng Li¹, Yi Guo¹, Zhuo-Ying Tao¹, Shi-Hao Qin¹,², Richard J Traub³, Hong An², and Dong-Yuan Cao¹

Abstract
Oxytocin (OT) is recognized as a critical neuropeptide in pain-related disorders. Chronic pain caused by the comorbidity of temporomandibular disorder (TMD) and fibromyalgia syndrome (FMS) is common, but whether OT plays an analgesic role in the comorbidity of TMD and FMS is unknown. Female rats with masseter muscle inflammation combined with 3-day forced swim (FS) stress developed somatic hypersensitivity, which modeled the comorbidity of TMD and FMS. Using this model, the effects of spinal OT administration on mechanical allodynia and thermal hyperalgesia in hindpaws were examined. Furthermore, the protein levels of OT receptors and 5-HT₂A receptors in the L4–L5 spinal dorsal horn were analyzed by Western blot. The OT receptor antagonist atosiban and 5-HT₂A receptor antagonist ritanserin were intrathecally injected prior to OT injection in the separate groups. Intrathecal injection of 0.125 μg and 0.5 μg OT attenuated the hindpaw hyperalgesia. The expression of OT receptors and 5-HT₂A receptors in the L4–L5 spinal dorsal horn significantly increased following intrathecal injection of 0.5 μg OT. Intrathecal administration of either the OT receptor antagonist atosiban or 5-HT₂A receptor antagonist ritanserin blocked the analgesic effect of OT. These results suggest that OT may inhibit hindpaw hyperalgesia evoked by orofacial inflammation combined with stress through OT receptors and/or 5-HT₂A receptors, thus providing a therapeutic prospect for drugs targeting the OT system and for patients with comorbidity of TMD and FMS.

Keywords
oxytocin, serotonin, temporomandibular disorder, fibromyalgia syndrome, pain

Introduction
There exists a group of patients who experience a significant level of pain which cannot be classified as a symptom of a disease. These pain syndromes were newly termed chronic primary pain by the International Classification of Diseases-11 (ICD-11).¹,² Chronic primary pain is a chronic relapsing pain condition that has gained recognition in the recent years. The origin of the chronic primary pain is difficult to trace since there is no definitive physical pathology or available laboratory measures for chronic primary pain.¹,³ Chronic headache, neck pain, back pain, pelvic pain, irritable bowel syndrome (IBS), fibromyalgia syndrome (FMS), and temporomandibular disorder (TMD) are examples of chronic primary pain.³ More often than not, multiple chronic pain conditions co-occur in the same individual.

¹Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, Research Center of Stomatolgy, Xi’an Jiaotong University College of Stomatolgy, China
²Department of Special Dental Care, Xi’an Jiaotong University College of Stomatolgy, China
³Department of Neural and Pain Sciences, School of Dentistry, Center to Advance Chronic Pain Research, University of Maryland Baltimore, Baltimore, MD, USA

Corresponding Authors:
Hong An, Department of Special Dental Care, Xi’an Jiaotong University College of Stomatolgy, Xi’an, Shaanx 710004, China.
Email: anhong@mail.xjtu.edu.cn
Dong-Yuan Cao, Research Center of Stomatolgy, Xi’an Jiaotong University College of Stomatolgy, Xi’an, Shaanx 710004, China.
Email: dongyuan_cao@hotmail.com
patient and are referred to as chronic overlapping pain conditions.

The features of TMD include pain in the temporomandibular joint and/or the masticatory muscles, limitations in mandibular motion, and clicking or crepitation produced by the temporomandibular joint during mandibular function. More than 50% of patients with TMD report pain conditions at sites beyond the masticatory system.4,6 For example, as many as 94% of patients with TMD are commonly diagnosed with FMS.7-9 However, despite its commonality, there are limited treatment strategies for the comorbidity of TMD and FMS in the clinic.4

Chronic primary pain is related to psychological distress.1,3 For example, in patients with TMD and FMS, there is a close association between exposure to stressful stimuli and exacerbation of pain symptoms.10-12 In fact, both human and animal studies have reported a causative role of stress in the development of pain. A large proportion of FMS patients report experiencing physical or sexual abuse in their childhood.13 In animals, stress such as forced swim (FS) or cold stress induces somatic hyperalgesia which can last for weeks.14-18 Thus, stress is a major triggering factor for both the generation of hyperalgesia and its aggravation.

One mechanism to account for the comorbidity between TMD and FMS is an imbalance of neurotransmitters causing augmented pain processing in the central nervous system (CNS), which is the chief pathology of FMS.19 The oxytocinergic system is activated under different conditions such as inflammatory sensitization,20 neuropathic pain,21, 22 or FS stress. Oxytocin (OT) is a nonapeptide synthesized by hypothalamic neurons. OT receptors play a vital role in pain modulation.23, 24 In the CNS, OT receptors can be coupled with both Gq and Gi proteins.25 The inhibitory effect of OT on the firing properties of sensory wide dynamic range (WDR) neurons in the spinal cord is through OT receptor functionally binding a Gi protein.26 FS significantly increased the release of OT within both the supraoptic nucleus and the paraventricular nucleus (PVN).26 In a rat inflammatory pain model induced by carrageenan, spinal OT increased for at least 24 h, and OT receptor activation led to sustained GABAergic activity.27 Intrathecal administration of OT affected the neuronal activity of Aδ and C fibers in rats, and the analgesic effect caused by spinal administration of OT was blocked by an OT receptor antagonist.28 Similarly, the analgesic effect induced by endogenous OT was also blocked by an OT receptor antagonist at the spinal level in rats.20

However, not all OT-provoked actions have been linked to its cognate receptors. OT receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors are expressed in similar brain regions modulating central pathways related to nociceptive behaviors.29 The participation of OT in modulating the serotonin (5-hydroxytryptamine, 5-HT) system has been demonstrated in multiple studies.30-33 Serotonergic projections innervate almost every brain region, and 5-HT is a key neurotransmitter involved in mood, stress, and social behaviors.34 Interestingly, OT is known to affect the synthesis and release of 5-HT from 5-HT neurons in the median raphe nuclei, reducing anxiety-like behaviors in mice.31 In addition, 5-HT receptors have been shown to mediate OT secretion from the PVN of the hypothalamus.35-37 Although OT and 5-HT2A receptors have been suggested to be involved in somatic hyperalgesia, the precise mechanism of OT and 5-HT2A receptor interaction has not yet been fully elucidated.

In our previous study, we established a rat model of TMD comorbid with FMS. Specifically, injection of complete Freund’s adjuvant (CFA) into masseter muscles induced orofacial inflammation in female rats. Then rats with pre-existing masseter muscle inflammation that were exposed to 3-day FS stress developed somatic pain hypersensitivity that persisted for 2 weeks. In the model, masseter muscle inflammation was used to mimic the symptoms of TMD, while FS provided the physical and psychological stress.38-40

Using this model in female rats, through testing both mechanical withdrawal threshold and thermal withdrawal latency, the effects of OT on the mechanical allodynia and thermal hyperalgesia were evaluated. Western blot was used to investigate the expression of spinal OT receptors and 5-HT2A receptors post intrathecal injection of OT. The OT receptor antagonist atosiban or 5-HT2A receptor antagonist rintanserin was intrathecally applied before OT injection to confirm the functional role of these two receptors. Generally, this study provides evidence for the therapeutic prospect of drugs targeting the OT system for patients with comorbid TMD and FMS.

Materials and Methods

Animals

Female Sprague–Dawley rats weighing 200–230 g were obtained from Xi’an Jiaotong University Laboratory Animal Center (Xi’an, Shaanxi, China). All animals were housed in a room temperature (22°C) controlled environment with a 12 h/12 h alternating light-dark cycle, with lights on at 7:00 a.m. Rats were housed in pairs, and food and water were available ad libitum. Experimental protocols were approved by the Institutional Animal Care and Use Committee of Xi’an Jiaotong University, China and adhered to the guidelines for experimental pain in animals published by the International Association for the Study of Pain.

Drugs

17β-estradiol (E2; Sigma, St Louis, MO, USA) was dissolved in safflower oil to a concentration of 0.5 mg/mL. CFA (Sigma) was dissolved in saline at a 1:1 ratio. OT (Sigma) was dissolved in 0.9% sterilized saline to a concentration of 50 μg/mL. The OT receptor antagonist atosiban (Sigma) was dissolved in 0.9% sterilized saline to a final concentration of 0.1 μg/10 μL. The 5-HT2A receptor antagonist rintanserin
(Sigma) was dissolved in 20% dimethyl sulfoxide (DMSO, MP Biomedicals, Irvine, CA, USA) to a final concentration of 20 μg/10 μL. Intrathecal administration of 20% DMSO has no significant effect on pain behaviors in rats according to our results and other studies.

**Rat model of TMD comorbid with FMS**

Rats were anesthetized with isoflurane mixed with air (5% induction reduced to 3%) and ovariectomized (OVx) by a dorsolateral approach. Ten days after surgery, rats were subcutaneously injected with E2 (50 μg/100 μL), which was repeated at 4-days intervals to mimic the fluctuation of a normal estrous cycle. CFA (150 μL, 1:1 in saline) was injected into the masseter muscles bilaterally. Sub-chronic stress was induced by a 3-day FS paradigm starting 1 day after CFA injection. During the FS, rats were placed in a cylindrical container (30 cm diameter) filled with 20 cm water at 25–26°C for 10 min on the first day and 20 min on the following 2 days. After exposure to FS, rats were gently dried with a towel and a heater fan. The FS stress was performed at the same time from 9:00 a.m. to noon every day to avoid the influence of circadian rhythm.

**Behavioral experiment protocol**

The experimental procedures are shown in Figure 1. The mechanical withdrawal threshold was tested 30 min before injection of OT and 1, 2, 3, 4, 5, 6, and 7 h after the application of OT. The thermal withdrawal latency was tested before and 1, 3, and 5 h after injection of OT (testing took too long to retest hourly).

In order to investigate the effect of spinal OT receptors, rats were randomly assigned to the atosiban + OT group or saline + OT group. In the atosiban + OT group, the selective OT receptor antagonist atosiban (0.1 μg/10 μL) was intrathecally injected 30 min prior to injection of 0.5 μg OT. The control (saline + OT) group received an equal volume of 0.9% saline (10 μL, vehicle of atosiban) before OT injection.

To test the potential role of spinal 5-HT2A receptors in OT-induced analgesia, the effect of intrathecal application of the 5-HT2A receptor antagonist ritanserin was examined. Rats were randomly assigned to the ritanserin + OT group or DMSO + OT group. Rats in the ritanserin + OT group were given 20 μg/10 μL ritanserin 30 min before injection of 0.5 μg OT. The control (DMSO + OT) group received an equal volume of 20% DMSO (10 μL, vehicle of ritanserin) before OT injection.

**Behavioral measurements**

**Mechanical withdrawal threshold.** All behavioral tests were performed in the laboratory at stable temperatures (22 ± 1°C). The mechanical sensitivity was measured via a series of calibrated von Frey filaments according to the up and down method. In brief, each rat was placed in an individual Plexiglas chamber (20 × 20 × 25 cm) with a metal mesh floor and allowed to acclimate for at least 30 min before testing. Calibrated von Frey filaments with a range of force from 0.41 to 26 g (4–255 mN) were pressed perpendicularly against the left hindpaw plantar surface. The 26 g filament was the cut-off force to avoid excessive tissue injury. If there was no response to the initially selected filament, the next stronger stimulus was selected. If there was a withdrawal response, the next weaker stimulus was tested. After the first positive response, more stimuli were tested. Including the first positive stimulus, the six responses were used to calculate the threshold. The mean threshold of three consecutive successful trials was taken as the final threshold. Each rat was tested for a total of 20 trials.

**Figure 1.** Schematic experimental protocols. All rats were ovariectomized (OVx). After 10 days recovery, E2 was injected subcutaneously every 4 days. The baselines of mechanical withdrawal threshold (M) and thermal withdrawal latency (T) were tested prior to CFA injection. On the 4th, 8th, and 12th days post the last FS, the mechanical withdrawal threshold and thermal withdrawal latency were measured separately for each OT concentration group.
withdrawal threshold using the threshold calculation software (JFlash Dixon Calculator, University of Arizona, USA).

**Thermal withdrawal latency.** Rats were placed in separate clear Plexiglas chambers on an elevated glass surface and allowed to acclimate for 30 min before testing. An infrared (IR) beam was emitted and focused on the plantar surface of the right hindpaw, and the paw withdrawal latency was recorded by the equipment automatically. A 20 s cut-off was set to avoid excessive tissue injury. Three records were collected per animal with an inter-stimulus interval of no less than 5 min. The average of the three trials was determined as the thermal withdrawal latency.

**Intrathecal administration**

Rats were anesthetized with isoflurane as described above. After shaving the injection area, rats were placed in a prone position with a round tube underneath the abdomen. A disposable 30-gauge needle connected to a 25 μL Luer tip Hamilton syringe was inserted at the intervertebral space between the L4–L5 vertebrae to penetrate the dura. A quick flick of the tail indicated the needle entering the intrathecal space. The drug or vehicle was injected over 1 min and then the needle was withdrawn.

**Western blot**

Rats were injected with either OT (0.5 μg) or sterile saline on the 4th day after FS stress. Three hours later (the time of maximum efficacy of OT), rats were anesthetized with isoflurane (5%) and decapitated. The spinal cord was removed by pressure ejection with ice-cold saline. The L4–L5 section of the dorsal spinal cord was isolated and stored at −80°C until use.

Tissues were homogenized in RIPA buffer (1% NP-40, 1% sodium deoxycholate, and 0.1% SDS) and protease inhibitor cocktail (Boster, AR1182, Wuhan, China). The homogenates were centrifuged at 10,000 g for 10 min at 4°C, and the supernatants were obtained. Protein concentration in supernatants was measured via the bicinchoninic acid (BCA, Boster, AR0146) method. Protein samples (20 μg) were boiled for denaturing, fractionated 18 μg per lane on 4–12% SDS-PAGE gel (Boster, AR0138) and blotted to PVDF membranes (Millipore, IPVH00010, Darmstadt, Germany). The membranes were immunoblotted using 5% nonfat milk and then incubated with primary antibody directed against OT receptor (1:5000, Abcam, EPR12789, Cambridge, MA, USA), 5-HT2A Receptor (1:4000, Bioss, bs-12,049R, Beijing, China), and GAPDH (1:4000, Boster, BA2913) at 4°C overnight, respectively. The membranes were further incubated for 1 h in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH = 7.4–7.6) buffer with goat anti-rabbit secondary antibody (Boster, BA1054) at a 1:4000 dilution. The antigen-antibody complexes were visualized by enhanced chemiluminescence (Thermo Scientific, Waltham, MA, USA). The immunoreactive band densities were analyzed using Image J 18.0 software (available at: https://imagej.net).

**Data analysis**

All data are presented as mean ± SEM. Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, San Diego, CA, USA). The paired Student’s t-test was used to identify the rats’ hyperalgesia condition, and the unpaired Student’s t-test was used for testing the protein levels of the OT and 5-HT2A receptors. Two-way ANOVA followed by Sidak’s post hoc test was used to examine the differences in the pain behaviors among different OT concentration groups, and for intra-group comparisons. One-way ANOVA followed by Dunnett post hoc test was used for comparing post-application of OT receptor antagonist atosiban/5-HT2A receptor antagonist ritanserin and the analgesic effect of OT on the mechanical withdrawal threshold and thermal withdrawal latency. P < 0.05 was considered statistically significant.

**Results**

**Intrathecal injection of OT has an analgesic effect**

**Administration of OT reverses mechanical allodynia.** Injection of CFA into the masseter muscles combined with 3-day repeated FS stress lowered the hindpaw mechanical withdrawal threshold on the 4th day after the last FS compared with baseline (paired Student’s t-test, p < 0.0001, Figure 2(A)). OT at 0.125 and 0.5 μg inhibited mechanical allodynia (two-way ANOVA, F14,126 = 4.309, p < 0.0001 for interaction; F3, 63 = 12.67, p < 0.0001 for time factor; F2, 18 = 87.09, p < 0.0001 for group factor, Figure 2(B)). The analgesic effect of OT on mechanical stimuli lasted over the period from 2 to 4 h after 0.5 μg OT injection. After application of 0.125 μg OT, the mechanical withdrawal threshold peaked at 4 h. There was no significant difference in the mechanical withdrawal threshold after injection of 0.031 μg OT compared with pre-OT injection (p > 0.05).

**Administration of OT reverses thermal hyperalgesia.** Following orofacial inflammation combined with FS stress, rats displayed thermal hyperalgesia as represented by the significant decrease in thermal withdrawal latency (paired Student’s t-test, p < 0.0001, Figure 3(A)). Both 0.125 μg and 0.5 μg dose, but not of 0.031 μg of OT inhibited the thermal hyperalgesia (two-way ANOVA, F6, 63 = 7.829, p < 0.0001 for interaction; F3, 63 = 53.48, p < 0.0001 for time factor; F2, 21 = 72.69, p < 0.0001 for group factor, Figure 3(B)). After injection of 0.5 μg OT, thermal withdrawal latency significantly increased at 1, 3, and 5 h (p < 0.0001 for 1 and 3 h and p = 0.0212 for 5 h). Administration of 0.125 μg OT induced an analgesic effect at 1 and 3 h compared with pre-OT injection (p = 0.001 and p < 0.0001, respectively). Taken together,
these results suggest that OT inhibits both mechanical allodynia and thermal hyperalgesia.

**OT increases the expression of OT receptors in the spinal cord**

The effects of OT on OT receptor expression were examined 4 days following the end of the stress paradigm. Three hours following OT injection (0.5 μg), the protein level of OT receptors in the L4–L5 spinal dorsal horn was significantly up-regulated post OT application compared with the control (saline) group (unpaired Student’s t-test, p = 0.0016, Figure 4(A)). These data suggest that OT receptors in the spinal cord are involved in the modulation of OT in alleviating hindpaw hyperalgesia induced by orofacial inflammation combined with FS stress.

**Pretreatment with OT receptor antagonist atosiban blocks the analgesic effect of OT**

To further confirm the role of OT receptors in OT-mediated inhibition of hindpaw hyperalgesia induced by orofacial inflammation combined with FS stress, the behavioral responses of rats to mechanical and thermal stimuli were investigated after intrathecal injection of OT receptor antagonist atosiban on the 4th day after FS stress. Intrathecal injection of atosiban (0.1 μg) reversed the thermal hyperalgesia induced by orofacial inflammation combined with FS stress. #, **** p < 0.05, 0.001, 0.0001 vs. pre-OT with the same dose, respectively. Pre-OT represents the time point 30 min before OT injection. N = 7 in each group.
OT increases the expression of 5-HT\textsubscript{2A} receptors in the spinal cord

Both OT receptors and 5-HT\textsubscript{2A} receptors are involved in pain and stress related behaviors within brain regions. Therefore, an interaction between OT and 5-HT\textsubscript{2A} receptors in the L4–L5 spinal dorsal horn was examined. Intrathecal injection of OT (0.5 \( \mu \)g) increased 5-HT\textsubscript{2A} receptor expression compared with injection of saline (unpaired Student’s t-test, \( p = 0.0495 \); Figure 5(A)). Therefore, aside from OT receptors in the spinal cord, 5-HT\textsubscript{2A} receptors may also be affected by OT, alleviating hindpaw hyperalgesia induced by orofacial inflammation combined with FS stress.

Pretreatment with 5-HT\textsubscript{2A} receptor antagonist ritanserin blocks the analgesic effect of OT

Since Western blot data showed that 5-HT\textsubscript{2A} receptor expression significantly increased in the OT group compared with the control group, the changes of mechanical withdrawal threshold and thermal withdrawal latency were further investigated after intrathecal injection of 5-HT\textsubscript{2A} receptor antagonist ritanserin. Intrathecal administration of ritanserin (20 \( \mu \)g) reversed the analgesic effect of OT on both the mechanical withdrawal threshold (one-way ANOVA, \( F_{2, 21} = 9.313, p = 0.0037, \) Figure 5(B)) and thermal withdrawal latency (\( F_{2, 21} = 18.39, p < 0.0001, \) Figure 5(C)). Pre-injection of the vehicle (DMSO) had no effect. Both the behavioral and Western blot results suggest that administration of OT inhibits hindpaw hyperalgesia through an up-regulation of 5-HT\textsubscript{2A} receptors in the spinal cord.

Discussion

In the present study, we found that intrathecal injection of OT blocked hindpaw hyperalgesia induced by orofacial inflammation combined with repeated FS stress in female rats. This extends our previous observations that orofacial inflammation plus stress increases pain in other areas of the body away from the head.\textsuperscript{39, 40, 54} In the current study, OT increased the expression of both OT receptors and 5-HT\textsubscript{2A} receptors (but not 5-HT\textsubscript{2C} receptors, data not shown) in the spinal cord. Moreover, the analgesic function of OT was blocked by intrathecal administration of either the OT receptor antagonist atosiban or the 5-HT\textsubscript{2A/2C} receptor antagonist ritanserin, which is selective for 5-HT\textsubscript{2A} and 5-HT\textsubscript{2C} receptors over other 5-HT receptors. The results are consistent with the
findings that intraperitoneal OT significantly increases cardio OT receptor mRNA expression at 2 h after OT treatment and intranasal OT induces higher OT receptor expression in affected subcortical brain regions than unaffected regions. OT locates in about half of 5-HT neurons in the median raphe nucleus and OT affects the release of 5-HT from 5-HT neurons. Therefore, it is speculated that OT may facilitate the synthesis and accumulation of OT receptors and 5-HT2A receptors in the spinal cord after OT is intrathecally injected. These results indicate that the inhibition of OT in the spinal cord on hindpaw hyperalgesia induced by orofacial inflammation combined with FS stress is not only through the activation of OT receptors, but also through the involvement of 5-HT2A receptors. In the previous study, we found that CFA alone, 3-day FS stress alone and estrogen alone did not induce hindpaw hyperalgesia; therefore, we did not examine the effects of OT on these animals. The estrogen treated rats with 3-day FS stress were also not tested in the present study because the lasting time of hindpaw hyperalgesia occurred in these rats was shorter than that in the estrogen treated rats with orofacial inflammation plus 3-day FS stress.

The analgesic effects of OT have been investigated in both the central and peripheral nervous systems in numerous animal pain models. At the supraspinal level, OT has anti-nociceptive effects if OT is injected into the periaqueductal gray (PAG), raphe magnus, lateral ventricle, or the lateral habenular nucleus. Intracerebroventricular injection of OT significantly attenuated hindpaw incision-induced hyperalgesia; a dose-dependent inhibition of mechanical hypersensitivity was detected 30 min post administration of OT which lasted for 3 h. Administration of OT into the trigeminal ganglion decreased activities in sensitized neurons and inhibited orofacial mechanical allodynia triggered by partial ligation of the infraorbital nerve. The evidence of OT-induced analgesia at both peripheral and supraspinal levels indicates that OT may have a therapeutic effect on neuropathic pain.

When OT was injected into the intrathecal space, neuropathic pain induced by spinal nerve ligation was inhibited in a dose-dependent manner. Moreover, a single intrathecal injection of OT produced significant analgesia for 1 h in rats with neuropathic pain. When OT was continually administered intrathecally for the first 3 days after peripheral nerve injury, the prevention of neuropathic pain lasted for 2 days after OT administration. Intrathecal injection of OT also inhibited inflammatory hyperalgesia induced by carrageenan in rats. These findings indicate an analgesic effect of OT in attenuating neuropathic and inflammatory hyperalgesia.

An important additional consideration is the frequent co-occurrence of overlapping pain conditions and psychological

![Figure 5. 5-HT2A receptors contributed to the inhibitory effect of OT on hindpaw hyperalgesia.](image)
stress. In our animal model, psychological stress in the form of FS is a trigger factor for pain, while orofacial inflammation is critical for the generation and aggravation of TMD symptoms. FMS is characterized by somatic hyperalgesia, a clinical symptom that can be translated into animal models by measuring mechanical withdrawal threshold and thermal withdrawal latency. Therefore, the hindpaw hyperalgesia model induced by orofacial inflammation combined with FS stress utilized in the present study may mimic the comorbidity of TMD and FMS. Both the thermal withdrawal latency and mechanical withdrawal threshold decreased in the hindpaws in these animals. We demonstrated that spinal administration of OT reversed both mechanical allodynia and thermal hyperalgesia. The peak value and duration of analgesia in 0.5 μg OT group were higher and longer than 0.125 μg OT group. But there was no significant difference in the mechanical and thermal thresholds after injection of 0.031 μg OT compared with pre-OT injection. Thus, these data suggest that OT may provide a therapeutic prospect for treating patients with comorbid TMD and FMS. To examine how long the analgesic effects of OT maintain, the mechanical withdrawal latency was tested hourly and the thermal withdrawal latency was measured at 1, 3, and 5 h after injection of OT. These repetitive stimuli might have adversely impacted on the mechanical/thermal sensitivity and make rats more sensitive to mechanical and thermal tests.

The evidence of OT modulating pain perception in humans is less substantive than that in animals. However, several studies have found that exogenous OT administration reliably reduces pain sensitivity. For example, in a placebo-controlled study, intrathecal injection of OT relieved low back pain. A clinical study on IBS showed that intravenous controlled study, intrathecal injection of OT relieved low back pain. Therefore, OT administration reversed both mechanical allodynia and thermal hyperalgesia. The peak value and duration of analgesia in 0.5 μg OT group were higher and longer than 0.125 μg OT group. But there was no significant difference in the mechanical and thermal thresholds after injection of 0.031 μg OT compared with pre-OT injection. Thus, these data suggest that OT may provide a therapeutic prospect for treating patients with comorbid TMD and FMS. To examine how long the analgesic effects of OT maintain, the mechanical withdrawal latency was tested hourly and the thermal withdrawal latency was measured at 1, 3, and 5 h after injection of OT. These repetitive stimuli might have adversely impacted on the mechanical/thermal sensitivity and make rats more sensitive to mechanical and thermal tests.

The evidence of OT modulating pain perception in humans is less substantive than that in animals. However, several studies have found that exogenous OT administration reliably reduces pain sensitivity. For example, in a placebo-controlled study, intrathecal injection of OT relieved low back pain. A clinical study on IBS showed that intravenous controlled study, intrathecal injection of OT relieved low back pain. Therefore, OT administration reversed both mechanical allodynia and thermal hyperalgesia. The peak value and duration of analgesia in 0.5 μg OT group were higher and longer than 0.125 μg OT group. But there was no significant difference in the mechanical and thermal thresholds after injection of 0.031 μg OT compared with pre-OT injection. Thus, these data suggest that OT may provide a therapeutic prospect for treating patients with comorbid TMD and FMS. To examine how long the analgesic effects of OT maintain, the mechanical withdrawal latency was tested hourly and the thermal withdrawal latency was measured at 1, 3, and 5 h after injection of OT. These repetitive stimuli might have adversely impacted on the mechanical/thermal sensitivity and make rats more sensitive to mechanical and thermal tests.

The evidence of OT modulating pain perception in humans is less substantive than that in animals. However, several studies have found that exogenous OT administration reliably reduces pain sensitivity. For example, in a placebo-controlled study, intrathecal injection of OT relieved low back pain. A clinical study on IBS showed that intravenous controlled study, intrathecal injection of OT relieved low back pain. Therefore, OT administration reversed both mechanical allodynia and thermal hyperalgesia. The peak value and duration of analgesia in 0.5 μg OT group were higher and longer than 0.125 μg OT group. But there was no significant difference in the mechanical and thermal thresholds after injection of 0.031 μg OT compared with pre-OT injection. Thus, these data suggest that OT may provide a therapeutic prospect for treating patients with comorbid TMD and FMS. To examine how long the analgesic effects of OT maintain, the mechanical withdrawal latency was tested hourly and the thermal withdrawal latency was measured at 1, 3, and 5 h after injection of OT. These repetitive stimuli might have adversely impacted on the mechanical/thermal sensitivity and make rats more sensitive to mechanical and thermal tests.

The evidence of OT modulating pain perception in humans is less substantive than that in animals. However, several studies have found that exogenous OT administration reliably reduces pain sensitivity. For example, in a placebo-controlled study, intrathecal injection of OT relieved low back pain. A clinical study on IBS showed that intravenous controlled study, intrathecal injection of OT relieved low back pain. Therefore, OT administration reversed both mechanical allodynia and thermal hyperalgesia. The peak value and duration of analgesia in 0.5 μg OT group were higher and longer than 0.125 μg OT group. But there was no significant difference in the mechanical and thermal thresholds after injection of 0.031 μg OT compared with pre-OT injection. Thus, these data suggest that OT may provide a therapeutic prospect for treating patients with comorbid TMD and FMS. To examine how long the analgesic effects of OT maintain, the mechanical withdrawal latency was tested hourly and the thermal withdrawal latency was measured at 1, 3, and 5 h after injection of OT. These repetitive stimuli might have adversely impacted on the mechanical/thermal sensitivity and make rats more sensitive to mechanical and thermal tests.

The evidence of OT modulating pain perception in humans is less substantive than that in animals. However, several studies have found that exogenous OT administration reliably reduces pain sensitivity. For example, in a placebo-controlled study, intrathecal injection of OT relieved low back pain. A clinical study on IBS showed that intravenous controlled study, intrathecal injection of OT relieved low back pain. Therefore, OT administration reversed both mechanical allodynia and thermal hyperalgesia. The peak value and duration of analgesia in 0.5 μg OT group were higher and longer than 0.125 μg OT group. But there was no significant difference in the mechanical and thermal thresholds after injection of 0.031 μg OT compared with pre-OT injection. Thus, these data suggest that OT may provide a therapeutic prospect for treating patients with comorbid TMD and FMS. To examine how long the analgesic effects of OT maintain, the mechanical withdrawal latency was tested hourly and the thermal withdrawal latency was measured at 1, 3, and 5 h after injection of OT. These repetitive stimuli might have adversely impacted on the mechanical/thermal sensitivity and make rats more sensitive to mechanical and thermal tests.
the 5-HT2A receptor agonist, methylamine hydrobromide (TCB-2), increased pain thresholds and inhibited the incision-induced decrease in transcription and translation of KCC2, while the delivery of the 5-HT2A receptor antagonist ketanserin aggravated the hyperalgesia and decreased transcription and translation of KCC2. Similarly, administration of TCB-2 increased membrane KCC2 expression in the spinal dorsal horn and reduced the mechanical and thermal hyperalgesia in rats with spinal cord injury.

Parvocellular OT neurons located in the PVN synthesize OT and project extensively toward the brain stem and the spinal cord. These projections are strongly related to pain perception. In fact, OT administered by different methods has been shown to have an anti-nociceptive effect which is mediated by the activation of descending anti-nociceptive pathways to the spinal cord. The descending pain inhibitory system is an endogenous analgesic system mainly including the PAG, RVM, and the dorsal horn of the spinal cord. Electrophysiological, pharmacological, and behavioral data have shown that the paraventricular hypothalamic descending OT pathway participates in anti-nociceptive processes.

In the hypothalamo-spinal projection, parvocellular OT neurons in the PVN directly project to the WDR neurons in the deep layers of the spinal cord in rats. Both endogenous OT released from the PVN and exogenous OT administrated into the spinal level prevented and reduced long-term potentiation in spinal WDR neurons. In addition, after lesioning of the PVN, 5-HT2A receptors were activated, which mediated the release of OT. Selective stimulation of 5-HT2A receptors in the PVN also increased OT concentrations. Therefore, the activation of 5-HT2A receptors in the PVN may increase the endogenous secretion of OT. Moreover, when OT is released into the spinal cord, the 5-HT2A receptor-KCC2 pathway may also participate in analgesic processes.

The PAG and the RVM are closely associated areas noted for their function in the descending pain regulatory pathways. Injection of OT into the PAG had an analgesic function and administration of an OT receptor antagonist blocked this effect. In addition, pain stimulation elevated endogenous OT levels in the PAG, indicating that the PAG is a promising target for pain regulation through OT. OT may have anti-nociceptive role on the spinal cord neurons through PAG-RVM-spinal cord pathway. Thus, besides the direct analgesic effect of OT on the spinal cord circuitry, orofacial inflammation combined with FS stress may activate the PVN and increase the endogenous release of OT, which in turn inhibits pain perception through the PAG-RVM–spinal cord descending pathway and the direct hypothalamo-spinal projection. Further studies are needed to confirm the effects of endogenous OT.

Conclusion

The results of the present study indicate a therapeutic effect of OT in hindpaw hyperalgesia induced by orofacial inflammation combined with FS stress at the spinal level. Both OT receptors and 5-HT2A receptors are involved in OT’s alleviation of hindpaw hyperalgesia in female rats. Our findings provide a key insight that OT may be used as a novel therapy for the treatment of comorbid TMD and FMS.

Authorship Contribution

DYC designed the research; YXL, JHL, YG, ZYT, and SHQ performed the experiments; YXL, RJT, HA, and DYC analyzed the data and wrote the paper. All authors read and approved the final manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (81971049, 81671097) and the Social Development Program of Shaanxi Province, China (2020SF-018) to DYC, and partially by the National Institutes of Health, USA (R01 DE029074) to RJT.

ORCID iDs

Hong An https://orcid.org/0000-0003-2336-5291
Dong-Yuan Cao https://orcid.org/0000-0002-3994-2885

References

1. Tao ZY, Wang PX, Wei SQ, Traub RJ, Li JF, Cao DY. The role of descending pain modulation in chronic primary pain: potential application of drugs targeting serotonergic system. Neural Plast 2019; 2019: 1389296.
2. Nicholas M, Vlaeyen JWS, Rief W, Barke A, Aziz Q, Benoliel R, Cohen M, Evers S, Giamberardino MA, Goebel A, Korwisi B, Perrot S, Svensson P, Wang S-J, Treede R-D. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain 2019; 160: 28–37.
3. Sutar R, Yadav S, Desai G. Yoga intervention and functional pain syndromes: a selective review. Int Rev Psychiatry 2016; 28: 316–322.
4. Santos CEM, Rodrigues VP, De Oliveira ICV, De Assis DSFR, De Oliveira MM, Conti CF. Morphological changes in the temporomandibular joints in women with fibromyalgia and myofascial pain: A case series. Cranio 2021; 39: 440–444.
5. Harper DE, Schrepf A, Clauw DJ. Pain mechanisms and centralized pain in temporomandibular disorders. *J Dental Res* 2016; 95: 1102–1108.

6. Plesh O, Adams SH, Gansky SA. Temporomandibular joint and muscle disorder-type pain and comorbid pains in a national US sample. *J Orofacial Pain* 2011; 25: 190–198.

7. Moreno-Fernández AM, Jiménez-Castellanos E, Iglesias-Linares A, Bueso-Madrid D, Fernández-Rodríguez A, de Miguel M. Fibromyalgia syndrome and temporomandibular disorders with muscular pain. A review. *Mod Rheumatol* 2017; 27: 210–216.

8. Janal M, Raphael K, Cook D, Sirois D, Nemelivsky L, Staud R. Thermal temporal summation and decay of after-sensations in temporomandibular myofascial pain patients with and without comorbid fibromyalgia. *J Pain Res* 2016; 9: 641–652.

9. Leblebici B, Pektaş ZÖ, Hürçan EC, Bagis S, Akman MN. Coexistence of fibromyalgia, temporomandibular disorder, and masticatory myofascial pain syndromes. *Rheumatol Int* 2007; 27: 541–544.

10. Green PG, Alvarez P, Gear RW, Mendoza D, Levine JD. Further validation of a model of fibromyalgia syndrome in the rat. *J Pain* 2011; 12: 811–818.

11. Fillingim RB, Ohrbach R, Greenspan JD, Knott C, Dubner R, Bair E, Baraian C, Slade GD, Maixner W. Potential psychosocial risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. *J Pain* 2011; 12: T46–T60.

12. Pfau DB, Rolke R, Nickel R, Treede R-D, Daublaender M. Somatosensory profiles in subgroups of patients with myogenic temporomandibular disorders and fibromyalgia syndrome. *Pain* 2009; 147: 72–83.

13. McBeth J, Morris S, Benjamin S, Silman AJ, Macfarlane GJ. Associations between adverse events in childhood and chronic widespread pain in adulthood: are they explained by differential recall?. *J Rheumatology* 2001; 28: 2305–2309.

14. Quintero L, Sanchez A, Avila C, Arcaya J, Maixner W, Suarez-Roca H. Long-lasting delayed hyperalgesia after subchronic swim stress. *Pharmacol Biochem Behav* 2000; 67: 449–458.

15. Quintero L, Cuesta MC, Silva JA, Arcaya JL, Pinerua-Suhaibar L, Maixner W, Suarez-Roca H. Repeated swim stress increases pain-induced expression of c-Fos in the rat lumbar cord. *Brain Res* 2003; 965: 259–268.

16. Suarez-Roca H, Silva J, Arcaya J, Quintero L, Maixner W, Pinerua-Suhaibar L. Role of µ-opioid and NMDA receptors in the development and maintenance of repeated swim stress-induced thermal hyperalgesia. *Behav Brain Res* 2006; 167: 205–211.

17. Nishiyori M, Uchida H, Nagai J, Araki K, Mukae T, Kishioka S, Ueda H. Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants. *Mol Pain* 2011; 7: 69–78.

18. Ji Y, Hu B, Li J, Traub RJ. Opposing roles of estradiol and testosterone on stress-induced visceral hypersensitivity in rats. *J Pain* 2018; 19: 764–776.

19. Cheng CW, Wong CS, Hui GK, Chung EK, Wong SH. Fibromyalgia: is it a neuropathic pain? *Pain Manage* 2018; 8: 377–388.

20. Eliava M, Melchior M, Knobloch-Bollmann HS, Wahis J, da Silva Gouveia M, Tang Y, Ciobanu AC, Triana del Rio R, Roth LC, Althammer F, Chavant V, Goumon Y, Gruber T, Petit-Demoulière N, Busnelli M, Chini B, Tan LL, Mitre M, Froemke RC, Chao MV, Giese G, Sprengel R, Kuner R, Poisbeau P, Seeburg PH, Stoop R, Charlet A, Grinevich V. A new population of parvo/center hypofuscin fibers contains magnocellular neuron actiwy in inflammatory pain processing. *Neuron* 2016; 89: 1291–1304.

21. Guadalupe ML, Lizbeth EL, Martha C, Aramburo C. PVC electrical stimulation prolongs withdrawal latencies and releases oxytocin in cerebrospinal fluid, plasma, and spinal cord tissue in intact and neuropathic rats. *Pain* 2008; 140: 265–273.

22. Li X-H, Matsuura T, Xue M, Chen Q-Y, Liu R-H, Lu J-S, Shi W, Fan K, Zhou Z, Miao Z, Yang J, Wei S, Wei F, Chen T, Zhuo M. Oxytocin in the anterior cingulate cortex attenuates neuropathic pain and emotional anxiety by inhibiting presynaptic long-term potentiation. *Cel Rep* 2021; 36: 109411.

23. Tzabazis A, Mechanic J, Miller J, Kuklinov M, Pascual C, Manering N, Carson DS, Jacobs A, Qiao Y, Cuellar J, Frey WH, Jacobs D, Angst M, Yeomans DC. Oxytocin receptor: expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders. *Cephalalgia* 2016; 36: 943–950.

24. Gimel G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. *Physiol Rev* 2001; 81: 629–683.

25. Busnelli M, Saulière A, Manning M, Bouvier M, Galés C, Chini B. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. *J Biol Chem* 2012; 287: 3617–3629.

26. Wotjak CT, Gantner J, Kuhl G, Magazoff I, Landgraf R, Engelmann M. Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. *Neuroscience* 1998; 85: 1209–1222.

27. Juif P-E, Poisbeau P. Neurohormonal effects of oxytocin and vasopressin receptor agonists on spinal pain processing in male rats. *Pain* 2013; 154: 1449–1456.

28. Rojas-Piloni G, Gerardo RP, Mejia-Rodriguez R, Rosalinda MR, Martínez-Lorenzana G, Guadalupe ML, Condes-Lara M, Miguel CL. Oxytocin, but not vasopressin, modulates nociceptive responses in dorsal horn neurons. *Neurosci Letters* 2010; 476: 32–35.

29. Chruscicka B, Wallace Fitzsimons SE, Borroto-Escuela DO, Druelle C, Stampou Nally K, Dinan TG, Cryan JF, Fuxe K, Schellekens H. Attenuation of oxytocin and serotonin 2A receptor signaling through novel heteroreceptor formation. *ACS Chem Neurosci* 2019; 10: 3225–3240.
30. Gül DL, Ayeh D, Kee Wui H, Robert CM. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 2013; 501: 179–187.
31. Masahide Y, Yuki T, Kiyoshi I, Tadashi K, Larry JY, Tatsushi O, Katsuhiko N. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci 2009; 29: 2259–2271.
32. Eaton JL, Roache L, Nguyen KN, Cushing BS, Troyer E, Papademietrio E, Raghati MA. Organizational effects of oxytocin on serotonin innervation. Dev Psychobiol 2012; 54: 92–97.
33. Lefevre A, Richard N, Jazayeri M, Beuriat P-A, Fieux S, Zimmer L, Duhamel J-R, Sirigu A. Oxytocin and serotonin brain mechanisms in the nonhuman primate. J Neurosci 2017; 37: 6741–6750.
34. Lesch KP. Linking emotion to the social brain. The role of the serotonin transporter in human social behaviour. EMBO Reports 2007; 8 Spec No: S24–S29.
35. Yahong Z, Damjanoska KJ, Carrasco GA. Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. J Neurosci 2002; 22: 9635–9642.
36. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS. HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells. J Neurosci 2001; 21: 3572–3579.
37. Jørgensen H, Riis M, Knigge U, Warberg J, Riis M. Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 2003; 15: 242–249.
38. Ji Y, Hu B, Klontz C, Li J, Dessem D, Dorsey SG, Traub RJ. Peripheral mechanisms contribute to comorbid visceral hypersensitivity induced by preexisting orofacial pain and stress in female rats. Neurogastroenterol Motil 2020; 32: e13833-13843.
39. Traub RJ, Cao D-Y, Karpowicz J, Pandya S, Ji Y, Dorsey SG, Dessem D. A clinically relevant animal model of temporo-mandibular disorder and irritable bowel syndrome comorbidity. J Pain 2014; 15: 956–966.
40. Li J-J, Yang J-L, Wei S-Q, Li Z-L, Collins AA, Zou M, Wei F, Cao D-Y. Contribution of central sensitization to stress-induced spreading hyperalgesia in rats with orofacial inflammation. Mol Pain 2020; 13: 106–110.
41. Cao D-Y, Bai G, Ji Y, Traub RJ. Epigenetic upregulation of metabotropic glutamate receptor 2 in the spinal cord attenuates oestrogen-induced visceral hypersensitivity. Gut 2015; 64: 1913–1920.
42. Fossum EN, Lisowski MJ, Macey TA, Ingram SL, Morgan MM. Microinjection of the vehicle dimethyl sulfoxide (DMSO) into the periaqueductal gray modulates morphine antinociception. Brain Res 2008; 1204: 53–58.
43. Cao DY, Bai G, Ji Y, Karpowicz JM, Traub RJ. EXPRESS: Histone hyperacetylation modulates spinal type II metabotropic glutamate receptor alleviating stress-induced visceral hypersensitivity in female rats. Mol Pain 2016; 12: 174480691660722.
44. Sun W, Zhou Q, Ba X, Feng X, Hu X, Cheng X, Liu T, Guo J, Xiao L, Jiang J, Xiong D, Hao Y, Chen Z, Jiang C. Oxytocin relieves neuropathic pain through GABA release and presynaptic TRPV1 inhibition in spinal cord. Front Mol Neurosci 2018; 11: 248–260.
45. Benoussaid A, Maurin Y, Rampin O. Spinal effects of oxytocin on uterine motility in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R446–R453.
46. Yu S-Q, Lundeberg T, Yu L-C. Involvement of oxytocin in spinal antinociception in rats with inflammation. Brain Res 2003; 983: 13–22.
47. Zhang X-J, Zhang T-W., Hu S-J, Xu H. Behavioral assessments of the aversive quality of pain in animals. Neurosci Bull 2011; 27: 61–67.
48. Mizutani K, Sonoda S, Wakiha H. Ritanserin, a serotonin-2 receptor antagonist, inhibits functional recovery after cerebral infarction. Neuroreport 2018; 29: 54–58.
49. Barber A, Harting J, Wolf H-P. Antinociceptive effects of the 5-HT2 antagonist ritanserin in rats: Evidence for an activation of descending monoaminergic pathways in the spinal cord. Neurosci Lett 1989; 99: 234–238.
50. Crisp T, Stafinsky JL, Sponis LN, Uram M, Perni VC, Donepudi HB. Analgesic effects of serotonin and receptor-selective serotonin agonists in the rat spinal cord. Gen Pharmacol Vas Syst 1991; 22: 247–251.
51. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55–63.
52. Deuis JR, Dvorakova LS, Vetter I. Methods used to evaluate pain behaviors in rodents. Front Mol Neurosci 2017; 10: 284–290.
53. Li Y-X, An H, Wen Z, Tao Z-Y, Cao D-Y. Can oxytocin inhibit stress-induced hyperalgesia? Neuropeptides 2020; 79: 101996.
54. Xue Y, Wei S-Q, Wang P-X, Wang W-Y, Liu E-Q, Traub RJ, Cao D-Y. Down-regulation of Spinal 5-HT2A and 5-HT2C Receptors Contributes to Somatic Hyperalgesia induced by Orofacial Inflammation Combined with Stress. Neuroscience 2020; 440: 196–209.
55. Pournajafi-Nazarloo H, Papademeteriou E, Partoo L, Saadat H, Cushing BS. Modulation of cardiac oxytocin receptor and estrogen receptor alpha mRNAs expression following neonatal oxytocin treatment. Endocrine 2007; 31: 154–160.
56. Habets PC, McLain C, Meijer OC. Brain areas affected by intranasal oxytocin show higher oxytocin receptor expression. Eur J Neurosci 2021; 54: 6374–6381.
57. Condés-Lara M, González NM, Martínez-Lorenzana G, Delgado OL, Freund-Mercier MJ. Actions of oxytocin and interactions with glutamate on spontaneous and evoked dorsal spinal cord neuronal activities. Brain Res 2003; 976: 75–81.
58. Petersson M, Alster P, Lundeberg T, Uvnäs-Moberg K. Oxytocin increases nociceptive thresholds in a long-term
perspective in female and male rats. *Neurosci Lett* 1996; 212: 87–90.

59. Ge Y, Lundeberg T, Yu L-C. Blockade effect of mu and kappa opioid antagonists on the anti-nociception induced by intra-periaqueductal grey injection of oxytocin in rats. *Brain Res* 2002; 927: 204–207.

60. Wang J-W, Lundeberg T, Yu L-C. Antinociceptive role of oxytocin in the nucleus raphe magnus of rats, an involvement of μ-opioid receptor. *Regul Pept* 2003; 115: 153–159.

61. Gao L, Yu L-C. Involvement of opioid receptors in the oxytocin-induced antinociception in the central nervous system of rats. *Regul Pept* 2004; 120: 53–58.

62. Gao Q, Li D, Liu W, Xu X, Li H, Fu L, Wang Y. The participation of oxytocin in the abirritation of lateral habenular nucleus on normal adult rats. *Brain Res* 2015; 1602: 106–110.

63. Zhang Y, Yang Y, Dai R, Wu H, Li C, Guo Q. Oxytocin in the paraventricular nucleus attenuates incision-induced mechanical allodynia. *Exp Ther Med* 2015; 9: 1351–1356.

64. Kubo A, Shinoda M, Katagiri A, Takeda M, Suzuki T, Asaka J, Yeomans DC, Iwata K. Oxytocin alleviates orofacial mechanical hypersensitivity associated with infraorbital nerve injury through vasopressin-1A receptors of the rat trigeminal ganglia. *Pain* 2017; 158: 649–659.

65. Condés-Lara M, Maie IA, Dickenson AH. Oxytocin actions on afferent evoked spinal cord neuronal activities in neuropathic but not in normal rats. *Brain Res* 2005; 1045: 124–133.

66. Yang J. Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system. *Spine* 1994; 19: 867–871.

67. Louvel D, Delvaux M, Felez A, Fioramonti J, Bueno L, Lazorthes Y, Frexinios J. Oxytocin increases thresholds of colonic visceral perception in patients with irritable bowel syndrome. *Gut* 1996; 39: 741–747.

68. Wang Y-L, Yuan Y, Yang J, Wang C-H, Pan Y-J, Lu L, Wu Y-Q, Wang D-X, Lv L-X, Li R-R, Xue L, Wang X-H, Bi J-W, Liu X-F, Qian Y-N, Deng Z-K, Zhang Z-J, Zhai X-H, Zhou X-J, Wang G-L, Zhai J-X, Liu W-Y. The interaction between the oxytocin and pain modulation in headache patients. *Neuropeptides* 2013; 47: 93–97.

69. Oppong-Dameah A, Zaman RU, D’Souza MJ. Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin. *Horm Behav* 2019; 108: 20–29.

70. Pekarek BT, Hunt PJ, Arenkeli BR. Oxytocin and sensory network plasticity. *Front Neurosci* 2020; 14: 30.

71. Poisbeau P, Grinevich V, Charlet A. Oxytocin signaling in pain: cellular, circuit, system, and behavioral levels. *Curr Top Behav Neurosci* 2018; 35: 193–211.

72. Condés-Lara M, Martínez-Lorenzana G, Rojas-Piloni G, Rodríguez-Jiménez J. Branched oxytocinergic innervations from the paraventricular hypothalamic nuclei to superficial layers in the spinal cord. *Brain Res* 2007; 1160: 20–29.

73. Swanson LW, McKellar S. The distribution of oxytocin- and neurophysin-stained fibers in the spinal cord of the rat and monkey. *J Comp Neurol* 1979; 188: 87–106.

74. Boll S, Almeida de Minas AC, Raftogianni A, Herpertz SC, Grinevich V. Oxytocin and pain perception: from animal models to human research. *Neuroscience* 2018; 387: 149–161.

75. Xu S, Qin B, Shi A, Zhao J, Guo X, Dong L. Oxytocin inhibited stress induced visceral hypersensitivity, enteric glial cells activation, and release of proinflammatory cytokines in maternal separated rats. *Eur J Pharmacol* 2018; 818: 578–584.

76. de Jong TR, Veening JG, Olivier B, Waldinger MD. Oxytocin involvement in SSRI-induced delayed ejaculation: a review of animal studies. *J Sex Med* 2007; 4: 14–28.

77. Emiliano AFB, Cruz T, Pannoni V, Fudge JL. The interface of oxytocin-labeled cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for SSRIs therapeutic effects? *Neuropsychopharmacology* 2007; 32: 977–988.

78. Dong R, Yu B, Chen L, Yu W. The 5-HT2A receptor potassium-chloride cotransporter 2 signaling pathway in a rat incision pain model. *Exp Ther Med* 2016; 12: 3583–3588.

79. Okamoto K, Imbe H, Kimura A, Donishi T, Tamai Y, Senba E. Activation of central 5HT2A receptors reduces the craniofacial nociception of rats. *Neuroscience* 2007; 147: 1090–1102.

80. Ohata H, Saito S, Sasaki M, Goto F. Interactions of 5-HT2A receptor agonists with acetycholine in spinal analgesic mechanisms in rats with neuropathic pain. *Brain Res* 2003; 965: 114–120.

81. Schulte JT, Wierenga CJ, Bruining H. Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions. *Neurosci Biobehav Rev* 2018; 90: 260–271.

82. Sánchez-Brualia I, Boulenguez P, Brocard C, Liabeuf S. Activation of 5-HT2A receptors restores KCC2 function and reduces neuropathic pain after spinal cord injury. *Neuroscience* 2018; 387: 48–57.

83. Swanson LW, Sawchenko PE, Wiegand SJ, Price JL. Separate neurons in the paraventricular nucleus project to the median eminence and to the medulla or spinal cord. *Brain Res* 1980; 198: 190–195.

84. Condés-Lara M, Rojas-Piloni G, Martínez-Lorenzana G, Rodríguez-Jiménez J, López-Hidalgo M, Freund-Mercier MJ. Paraventricular hypothalamic influences on spinal nociceptive processing. *Brain Res* 2006; 1081: 126–137.

85. Miranda-Cardenas Y, Rojas-Piloni G, Martínez-Lorenzana G, Rodríguez-Jiménez J, López-Hidalgo M, Freund-Mercier MJ, Condés-Lara M. Oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist. *Pain* 2006; 122: 182–189.

86. Lau BK, Vaughan CW. Descending modulation of pain: the GABA disinhibition hypothesis of analgesia. *Curr Opin Neurol* 2014; 29: 159–164.

87. DeLaTorre S, Rojas-Piloni G, Martínez-Lorenzana G, Rodríguez-Jiménez J, Villanueva L, Condés-Lara M. Paraventricular oxytocinergic hypothalamic prevention or interruption of long-term potentiation in dorsal hom nociceptive
neurons: electrophysiological and behavioral evidence. *Pain* 2009; 144: 320–328.

88. Bagdy G, Makara GB. Hypothalamic paraventricular nucleus lesions differentially affect serotonin-1A (5-HT1A) and 5-HT2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses. *Endocrinology* 1994; 134: 1127–1131.

89. Bagdy G. Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. *Behav Brain Res* 1996; 73: 277–280.

90. Brooks JCW, Davies W-E, Pickering AE. Resolving the brainstem contributions to attentional analgesia. *J Neurosci* 2017; 37: 2279–2291.

91. Yang J, Li P, Liang J-Y, Pan Y-J, Yan X-Q, Yan F-L, Hao F, Zhang X-Y, Zhang J, Qiu P-Y, Wang D-X. Oxytocin in the periaqueductal grey regulates nociception in the rat. *Regul Pept* 2011; 169: 39–42.